Todos Medical Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Gerald E. Commissiong
- Full Time Employees
- 7
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 121 Derech Menachem Begin Tel Aviv Israel 6701203
- IPO Date
- Aug 24, 2017
- CIK
- 0001645260
- Website
- todosmedical.com
- Similar Companies
- Business
- Todos Medical Ltd. is an Israel-based clinical-stage in vitro diagnostics company specializing in the development and commercialization of novel blood tests for the early detection of cancer and neurodegenerative diseases, including Alzheimer's. Its core products and services include the Total Biochemical Infrared Analysis (TBIA) platform, which offers cancer screening via peripheral blood spectroscopy analyzing immune cell biochemical signatures; the Lymphocyte Proliferation Test (LymPro Test™) for diagnostic evaluation of neurodegenerative disorders; and a CLIA/CAP-certified laboratory facility, Provista Diagnostics, which offers PCR and antibody testing services. The company also operates a majority-owned subsidiary, 3CL Pharma Ltd., focused on developing therapeutics, diagnostics, and dietary supplements targeting 3CL protease biology with products such as Tollovir®, Tollovid®, and TolloTest™ for COVID-19 treatment and testing. Geographically, Todos Medical's operations span the United States, Israel, Singapore, and Europe with targeted commercial expansions into Southeast Asia. Recent major changes include the acquisition of key 3CL protease-related assets from NLC Pharma in 2022, forming 3CL Pharma and appointing Dr. Dorit Arad as Chief Scientific Officer; expansion into long COVID and COVID-19 testing services with the launch of nutraceutical Tollovid™, receiving FDA certificate of free sale; strategic partnerships for COVID-19 PCR testing distribution; initiation of genomic sequencing capabilities for COVID variant detection; and development of a mobile biosafety level 3 molecular laboratory infrastructure. The company is also progressing toward commercialization of TBIA technology in Singapore and Europe and expanding molecular testing services beyond COVID-19. Financially, it faces insolvency proceedings in Israel but is pursuing retooling focused on long COVID-related diagnostics and therapeutics. Founded in 2010 and headquartered in Tel Aviv, Israel, Todos Medical continues to innovate in diagnostic technologies with a multi-faceted product pipeline targeting oncology, infectious diseases, and neurodegenerative conditions.
Todos Med (OTCMKTS:TOMDF) and Aclarion (NASDAQ:ACON) Head-To-Head Survey
Reviewing Todos Med (OTCMKTS:TOMDF) & Auna (NYSE:AUNA)
Financial Analysis: GeneDx (NASDAQ:WGS) & Todos Med (OTCMKTS:TOMDF)
Todos Medical Announces Insolvency Proceedings in Israel
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients
Todos Medical enters LOI for Provista Diagnostics to license key PCR-based sepsis diagnostic test
Todos Medical expresses support for Long COVID sufferers, plans to study Tollovid's usefulness in patients
Todos Medical updates investors on its lab Provista Diagnostics, subsidiary 3CL Pharma, and Todos Botanicals automated retail rollout
Todos Medical says Provista Diagnostics lab kicks off validation plan for PCR-based bird flu test for humans
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference
Todos Medical signs agreement to sell supplements via Affy Services' Smart Automated Retail Network
Todos Medical finds major 3Q revenue bump from COVID-19 testing services
Todos Medical to Host Third Quarter 2022 Earnings and Business Update Conference Call on November 15, 2022
Todos Medical clinical laboratory Provista Diagnostics submits emergency use application for its PCR monkeypox test
Todos Medical pursuing New York Stock Exchange listing, it says in a wide-ranging update into new business developments
Todos Medical touts successful pilot launch of suite of PCR testing services by its lab Provista Diagnostics
Todos Medical set to be granted two patents for its TBIA pan-cancer blood diagnostics platform
Todos Medical announces receipt of notice of allowance for its 3CL protease biomarker diagnostics TolloTest
Todos Medical strikes $50M contact with Nerd Hemp to distribute Tollovid and CBD products in AI retail machines across the US